William Barton/iStock Editorial via Getty Images
GSK plc (GSK) reported third-quarter core earnings per share above analyst expectations on Wednesday, as growth in specialty medicines helped offset weakness in vaccines.
The drugmaker reaffirmed its full-year 2026 outlook, while investors continued to assess the growth potential of newer